Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
LakeShore Biopharma ( (LSBCF) ) has shared an update.
On February 6, 2026, LakeShore Biopharma disclosed that the buyer group behind its previously announced going-private deal at $0.90 per share has notified the company that recent arbitral awards totaling about RMB576.5 million in financial liabilities may constitute a “Company Material Adverse Effect” under the November 4, 2025 merger agreement. Citing this alleged material adverse effect, the buyer group asserted it has the right not to consummate the merger and said it would not attend or vote at the extraordinary general meeting (EGM) that had been scheduled for February 12, 2026 to approve the transaction, while signaling a willingness to discuss amended terms. In response, LakeShore Biopharma has postponed the EGM, will disregard all previously submitted proxy cards, and plans to review the buyer group’s claims and its strategic options, introducing new uncertainty for shareholders around the timing, pricing and even completion of the going‑private transaction.
The most recent analyst rating on (LSBCF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSBCF Stock Forecast page.
Spark’s Take on LSBCF Stock
According to Spark, TipRanks’ AI Analyst, LSBCF is a Neutral.
LakeShore Biopharma’s overall stock score is primarily impacted by its financial performance, which shows strong gross profit margins but significant challenges with profitability and cash flow. Technical analysis indicates a bearish trend, and the lack of valuation data further contributes to a lower score. The absence of earnings call and corporate events data means these components do not influence the score.
To see Spark’s full report on LSBCF stock, click here.
More about LakeShore Biopharma
LakeShore Biopharma Co., Ltd., formerly YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. Leveraging its proprietary PIKA immunomodulating technology platform, the company is developing preventive and therapeutic biologics targeting rabies, hepatitis B, influenza and other viral infections, and operates across China, Singapore and the Philippines under a management team with both local and international biopharma experience.
Average Trading Volume: 5,356
Technical Sentiment Signal: Sell
Current Market Cap: $35.03M
For an in-depth examination of LSBCF stock, go to TipRanks’ Overview page.